Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
PCI Biotech: First quarter 2016 report | ||
By: Nasdaq / GlobeNewswire - 03 May 2016 | Back to overview list |
|
Oslo, 3 May 2016 Please find attached the first quarter 2016 report for PCI Biotech Holding ASA. Highlights include:
CEO Per Walday comments:
The first research agreement in the field of cancer vaccination was also an important milestone for the company. Our preclinical research combining the PCI technology with peptide vaccines have demonstrated strong enhancement of important cellular immune responses. The research has already been initiated and we look forward to exploring synergistic effects in this collaboration with Ultimovacs. The strategic refocusing has resulted in three clearly defined development areas for fimaporfin (Amphinex), with the advantage of shared technological solutions in multiple business opportunities with different risk profiles."
About PCI Biotech
The company has a clinical Phase I/II program in bile duct cancer, which is an orphan indication without approved medicinal products and a high need for better local treatments. The indication is well suited for PCI treatment, with easy light access through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI. The company is also developing PCI as a vaccination technology. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines. The PCI technology is also very well suited for intracellular delivery of nucleic acids, such as RNA therapeutics. By releasing nucleic acid compounds from endosomes where they are trapped following administration, PCI addresses one of the major bottlenecks facing this emerging and exciting field. For more information visit: www.pcibiotech.com
Contact information:
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: PCI Biotech Holding via GlobeNewswire
HUG#2009108
|
||
|
||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |